title: Upstream effect for atrial fibrillation: still a dilemma?
authors.affiliation: Division of Cardiology, Policlinico Casilino ASL RMB, Rome, Italy.
authors.forename: Leonardo
authors.initials: L
authors.lastname: Calò
authors.forename: Annamaria
authors.initials: A
authors.lastname: Martino
authors.forename: Luigi
authors.initials: L
authors.lastname: Sciarra
authors.forename: Antonio
authors.initials: A
authors.lastname: Ciccaglioni
authors.forename: Ermenegildo
authors.initials: E
authors.lastname: De Ruvo
authors.forename: Lucia
authors.initials: L
authors.lastname: De Luca
authors.forename: Antonella
authors.initials: A
authors.lastname: Sette
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Giunta
authors.forename: Ernesto
authors.initials: E
authors.lastname: Lioy
authors.forename: Francesco
authors.initials: F
authors.lastname: Fedele
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use*; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D015525:Fatty Acids, Omega-3; D005938:Glucocorticoids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors